Method of treating multiple sclerosis with interferon-beta and an IL-2R antagonist
AssigneeThe United States of America, as represented by the Secretary, Department of Health and Human Services
InventorsRoland Martin, Henry McFarland, Bibiana Bielekova, Thomas Waldmann
Life of this patent
Estimating the term…
Abstract
Disclosed is a method of administering an interleukin-2 receptor (IL-2R) antagonist to a subject to treat an autoimmune disease. In particular embodiments, the IL-2R antagonist is an anti-IL-2R monoclonal antibody specific for one or more chains of the IL-2R, such as the alpha-chain, for example daclizumab. In other particular embodiments the autoimmune disease is multiple sclerosis. In certain embodiments administration of interferon-beta is combined with administration of an antagonist of the IL-2R to provide significant clinical improvement in a subject with an autoimmune disease.
Claims20
A method of treating a human subject that has multiple sclerosis comprising,
- administering to the human subject a therapeutically effective amount of interferon-beta and a therapeutically effective amount of an antibody that specifically binds an alpha subunit of a human high-affinity interleukin 2 receptor,
- thereby treating the human subject.
Dependencies are inferred from the claim text.